{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-056451","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.454270+00:00","generated_at":"2026-06-25T23:43:11.651339+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Natera Q1 revenue $194.1M (+27.5% YoY), raises 2022 guidance to $790-810M","bullets":["Product revenue $190M, up 57.8% YoY; processed 489,300 tests, up 40.5%.","Net loss $138.6M or ($1.45) per share vs. ($0.74) a year ago.","Raised 2022 revenue guidance from $770-790M to $790-810M.","Board and executives elect to take 100% equity compensation for remainder of 2022.","Signatera ADLT reimbursement increased to $3,920 per test effective April 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-056451","json":"https://secwatch.observer/filing/0001104659-22-056451.json","markdown":"https://secwatch.observer/filing/0001104659-22-056451.md","text":"https://secwatch.observer/filing/0001104659-22-056451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465922056451/0001104659-22-056451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465922056451/tm2214592d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:43:11.651339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}